Developer docs
API playgroundTry for free, no card

Search company profiles

Sardocor

Full company profile

uuid000etga

Namestring
Sardocor
Legal namestring
Sardocor Corp
Websiteurl
sardocor.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Sardocor is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. It operates as a wholly owned subsidiary of the Medera Group, developing gene and cell therapies for rare and common cardiovascular, pulmonary, and vascular diseases. The company's lead therapeutic modality is recombinant adeno-associated viral vector (AAV) gene therapy, specifically AAV serotype 1 capsid carrying the human SERCA2a gene (AAV1/SERCA2a), which targets calcium dysregulation in cardiomyocytes — a validated mechanism in heart failure pathology. The science is grounded in over three decades of foundational cardiac gene therapy research originated at Massachusetts General Hospital by founder Dr. Roger Hajjar.

Sardocor's clinical pipeline centers on SRD-001, its lead AAV1/SERCA2a gene therapy candidate delivered via a proprietary intracoronary infusion method. The company holds three open FDA Investigational New Drug (IND) approvals covering Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with HFpEF and DMD-CM designated as First-in-Human gene therapies for those indications. FDA Fast Track designation was granted to both the HFpEF and DMD-CM programs in early 2026. Manufacturing scale has reached 1,000 doses of SRD-001 available for patient dosing. The company also pursues earlier-stage programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure, and leverages Novoheart's bioengineered human mini-heart assays for disease modeling and dosing optimization under FDA Modernization Act 2.0.

The business model is pre-commercial: Sardocor is a pre-revenue, clinical-stage biotech that distributes its therapies exclusively through FDA-regulated clinical trial sites and intends to commercialize via traditional pharmaceutical channels post-approval. Revenue mechanics are expected to be one-time license/product sales of approved gene therapies rather than recurring subscription revenue. The company actively courts investor relationships to fund ongoing clinical development, has an Expanded Access program, and recruits patients directly through its website for trial enrollment. Its headcount of 11–50 reflects an early-stage operating footprint appropriate to a sponsor of three concurrent Phase-stage trials, with the parent Medera Group providing corporate infrastructure.

Short descriptiontext

Sardocor is a clinical-stage gene therapy subsidiary of Medera Group developing AAV1/SERCA2a treatments for heart failure and Duchenne Muscular Dystrophy-associated cardiomyopathy, with three FDA IND approvals and Fast Track designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac gene therapy, AAV gene therapy, heart failure therapeutics, Duchenne cardiomyopathy, SERCA2a gene transfer
Industry3 codes
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cardiac Gene Therapy Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing gene therapy products for heart failure and related cardiomyopathies. Revenue generation will come from FDA-approved gene therapy products commercialized after successful clinical trials.

sardocor.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sardocor develops gene therapies for cardiac, pulmonary, and vascular diseases using recombinant AAV1/SERCA2a vectors delivered via a proprietary intracoronary method. Its lead candidate SRD-001 has 1,000 doses manufactured and is being advanced through three FDA IND-approved clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with additional pipeline programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 1,000 doses of SRD001 manufactured and made available to patients
+1 more record
Product overview1 text field

Sardocor is a clinical-stage biopharmaceutical company developing novel gene therapies for cardiac, pulmonary, and vascular diseases. The company's lead product is SRD-001, a gene therapy delivered via a proprietary intracoronary method that has completed manufacturing of 1,000 doses. Sardocor operates three FDA IND-approved gene therapy clinical trials: HFpEF (Heart Failure with Preserved Ejection Fraction), HFrEF (Heart Failure with Reduced Ejection Fraction), and DMD-CM (Duchenne Muscular Dystrophy-associated Cardiomyopathy), with HFpEF and DMD-CM both receiving FDA Fast Track designation. The company leverages SERCA2a gene transfer technology using recombinant adeno-associated viral vectors (AAV) and bioengineered human heart-based assays from Novoheart for disease modeling. The pipeline also includes programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Product and service8 records
1SRD-001 Gene Therapy Candidate
CategoryCardiac Gene Therapy
Description

AAV1/SERCA2a gene therapy drug candidate administered via Sardocor's proprietary intracoronary delivery method to infuse gene therapy directly into the heart for patients with cardiac diseases. 1,000 doses have been manufactured.

2HFpEF Gene Therapy Clinical Program
CategoryCardiac Gene Therapy Clinical Program
Description

First-in-Human gene therapy clinical program targeting Heart Failure with preserved Ejection Fraction (HFpEF), a condition with no disease-modifying therapies currently available; granted FDA Fast Track designation.

3HFrEF Gene Therapy Clinical Program
CategoryCardiac Gene Therapy Clinical Program
Description

Gene therapy clinical program targeting Heart Failure with reduced Ejection Fraction (HFrEF), a progressive and irreversible syndrome; aims to restore SERCA2a function via AAV gene transfer.

4DMD-CM Gene Therapy Clinical Program
CategoryCardiac Gene Therapy Clinical Program
Description

First-in-Human gene therapy clinical program targeting cardiomyopathy in Duchenne Muscular Dystrophy (DMD-CM); granted FDA Fast Track designation.

5Pulmonary Hypertension Gene Therapy Program
CategoryPulmonary Gene Therapy Pipeline Program
Description

Pipeline gene therapy program targeting pulmonary hypertension, a condition where high blood pressure in the pulmonary arteries causes damage to the right side of the heart.

6Pulmonary Fibrosis Gene Therapy Program
CategoryPulmonary Gene Therapy Pipeline Program
Description

Pipeline gene therapy program targeting pulmonary fibrosis, a lung-scarring condition that blocks oxygen transfer into the bloodstream.

7Restenosis Gene Therapy Program
CategoryVascular Gene Therapy Pipeline Program
Description

Pipeline gene therapy program targeting restenosis, a condition where treated arteries become narrowed again after treatment.

8Arteriovenous Fistula Failure Gene Therapy Program
CategoryVascular Gene Therapy Pipeline Program
Description

Pipeline gene therapy program targeting arteriovenous fistula failure, where surgically created dialysis access never becomes usable or fails within three months.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sardocor is a fully owned subsidiary of Medera Group. Sardocor operates as a division of Medera, advancing a pipeline of disease-modifying gene therapies developed by the Medera team.

Strategic tierCoreTypeTechnology or Integration
Description

Sardocor uses Novoheart's proprietary, world's first human mini-heart technology for disease modelling and therapeutic discovery. This bioengineered human heart-based assay is used to titrate optimal dosages for gene therapy candidates in accordance with FDA Modernization Act 2.0 for human relevance and accuracy.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Established gene therapy company with AAV platform and programs in cardiovascular disease (e.g., AMT-101 for refractory angina using SERCA2a). Direct overlap on SERCA2a gene therapy mechanism and cardiovascular focus, but broader portfolio across multiple disease areas.

TypeDirect peer
Description

Clinical-stage biotech developing cell and exosome-based therapies for Duchenne muscular dystrophy and related cardiomyopathies. Direct overlap on DMD-CM indication and complementary cell/gene therapy modality for cardiac disease.

TypeBroad incumbent
Description

Commercial-stage gene therapy company with multiple approved and clinical-stage AAV products for rare diseases (e.g., Roctavian for hemophilia A). Comparable gene therapy modality and rare disease commercial strategy, though broader portfolio and much larger scale.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on cardiac and CNS indications, including AAV-based therapies for genetic cardiomyopathies and Friedreich's ataxia cardiomyopathy. Directly comparable platform (AAV gene therapy), indication overlap (cardiac), and stage (clinical).

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for rare diseases, with a cardiac program (RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy). Comparable platform technology and rare cardiac indication focus.

TypeDirect peer
Description

Omitted in favor of stronger direct peers above.

TypeDirect peer
Description

Clinical-stage biotech developing gene therapies for genetic and acquired heart disease, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy. Directly comparable AAV-based cardiac gene therapy platform and similar disease-modifying positioning.

TypeBroad incumbent
Description

Acquired by Bayer; develops AAV-based gene therapies across multiple disease areas including cardiac (congestive heart failure program based on Hajjar's earlier SERCA2a work licensed from Dr. Hajjar). Highly relevant incumbent that previously licensed the underlying SERCA2a technology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sardocor

Cardiac Gene Therapy Biopharmaceuticalssardocor.com

Sardocor is a clinical-stage gene therapy subsidiary of Medera Group developing AAV1/SERCA2a treatments for heart failure and Duchenne Muscular Dystrophy-associated cardiomyopathy, with three FDA IND approvals and Fast Track designations.

What Sardocor does

Sardocor is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. It operates as a wholly owned subsidiary of the Medera Group, developing gene and cell therapies for rare and common cardiovascular, pulmonary, and vascular diseases. The company's lead therapeutic modality is recombinant adeno-associated viral vector (AAV) gene therapy, specifically AAV serotype 1 capsid carrying the human SERCA2a gene (AAV1/SERCA2a), which targets calcium dysregulation in cardiomyocytes — a validated mechanism in heart failure pathology. The science is grounded in over three decades of foundational cardiac gene therapy research originated at Massachusetts General Hospital by founder Dr. Roger Hajjar.

Sardocor's clinical pipeline centers on SRD-001, its lead AAV1/SERCA2a gene therapy candidate delivered via a proprietary intracoronary infusion method. The company holds three open FDA Investigational New Drug (IND) approvals covering Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with HFpEF and DMD-CM designated as First-in-Human gene therapies for those indications. FDA Fast Track designation was granted to both the HFpEF and DMD-CM programs in early 2026. Manufacturing scale has reached 1,000 doses of SRD-001 available for patient dosing. The company also pursues earlier-stage programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure, and leverages Novoheart's bioengineered human mini-heart assays for disease modeling and dosing optimization under FDA Modernization Act 2.0.

The business model is pre-commercial: Sardocor is a pre-revenue, clinical-stage biotech that distributes its therapies exclusively through FDA-regulated clinical trial sites and intends to commercialize via traditional pharmaceutical channels post-approval. Revenue mechanics are expected to be one-time license/product sales of approved gene therapies rather than recurring subscription revenue. The company actively courts investor relationships to fund ongoing clinical development, has an Expanded Access program, and recruits patients directly through its website for trial enrollment. Its headcount of 11–50 reflects an early-stage operating footprint appropriate to a sponsor of three concurrent Phase-stage trials, with the parent Medera Group providing corporate infrastructure.

Sardocor firmographics

Firmographics
Name
Sardocor
Legal name
Sardocor Corp
Website
https://sardocor.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Sardocor is a clinical-stage gene therapy subsidiary of Medera Group developing AAV1/SERCA2a treatments for heart failure and Duchenne Muscular Dystrophy-associated cardiomyopathy, with three FDA IND approvals and Fast Track designations.
Ownership category
akta.pro rank

Sardocor industry classification

Industry
Product category
Cardiac Gene Therapy Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cardiac gene therapy
  • AAV gene therapy
  • Heart failure therapeutics
  • Duchenne cardiomyopathy
  • SERCA2a gene transfer

Where Sardocor is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sardocor business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Gene Therapy Commercialization: Pre-revenue clinical-stage biotech company developing gene therapy products for heart failure and related cardiomyopathies. Revenue generation will come from FDA-approved gene therapy products commercialized after successful clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Sardocor product offering

Product offering

Core offering

Sardocor develops gene therapies for cardiac, pulmonary, and vascular diseases using recombinant AAV1/SERCA2a vectors delivered via a proprietary intracoronary method. Its lead candidate SRD-001 has 1,000 doses manufactured and is being advanced through three FDA IND-approved clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with additional pipeline programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Product overview

Sardocor is a clinical-stage biopharmaceutical company developing novel gene therapies for cardiac, pulmonary, and vascular diseases. The company's lead product is SRD-001, a gene therapy delivered via a proprietary intracoronary method that has completed manufacturing of 1,000 doses. Sardocor operates three FDA IND-approved gene therapy clinical trials: HFpEF (Heart Failure with Preserved Ejection Fraction), HFrEF (Heart Failure with Reduced Ejection Fraction), and DMD-CM (Duchenne Muscular Dystrophy-associated Cardiomyopathy), with HFpEF and DMD-CM both receiving FDA Fast Track designation. The company leverages SERCA2a gene transfer technology using recombinant adeno-associated viral vectors (AAV) and bioengineered human heart-based assays from Novoheart for disease modeling. The pipeline also includes programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Differentiator

Problem solved

Functional benefit

Products and services

  • SRD-001 Gene Therapy Candidate AAV1/SERCA2a gene therapy drug candidate administered via Sardocor's proprietary intracoronary delivery method to infuse gene therapy directly into the heart for patients with cardiac diseases. 1,000 doses have been manufactured.
  • HFpEF Gene Therapy Clinical Program First-in-Human gene therapy clinical program targeting Heart Failure with preserved Ejection Fraction (HFpEF), a condition with no disease-modifying therapies currently available; granted FDA Fast Track designation.
  • HFrEF Gene Therapy Clinical Program Gene therapy clinical program targeting Heart Failure with reduced Ejection Fraction (HFrEF), a progressive and irreversible syndrome; aims to restore SERCA2a function via AAV gene transfer.
  • DMD-CM Gene Therapy Clinical Program First-in-Human gene therapy clinical program targeting cardiomyopathy in Duchenne Muscular Dystrophy (DMD-CM); granted FDA Fast Track designation.
  • Pulmonary Hypertension Gene Therapy Program Pipeline gene therapy program targeting pulmonary hypertension, a condition where high blood pressure in the pulmonary arteries causes damage to the right side of the heart.
  • Pulmonary Fibrosis Gene Therapy Program Pipeline gene therapy program targeting pulmonary fibrosis, a lung-scarring condition that blocks oxygen transfer into the bloodstream.
  • Restenosis Gene Therapy Program Pipeline gene therapy program targeting restenosis, a condition where treated arteries become narrowed again after treatment.
  • Arteriovenous Fistula Failure Gene Therapy Program Pipeline gene therapy program targeting arteriovenous fistula failure, where surgically created dialysis access never becomes usable or fails within three months.

Quantifiable outcome

  • 1,000 doses of SRD001 manufactured and made available to patients
  • +1 more outcomes

Companies that use Sardocor

Customer profile

Segments3 records

Ideal customer profiles2 records

Sardocor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sardocor partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Medera GroupcoreStrategic or Co-development PartnerSardocor is a fully owned subsidiary of Medera Group. Sardocor operates as a division of Medera, advancing a pipeline of disease-modifying gene therapies developed by the Medera team.
  • NovoheartcoreTechnology or IntegrationSardocor uses Novoheart's proprietary, world's first human mini-heart technology for disease modelling and therapeutic discovery. This bioengineered human heart-based assay is used to titrate optimal dosages for gene therapy candidates in accordance with FDA Modernization Act 2.0 for human relevance and accuracy.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Sardocor competitors and assessment

Company assessment

Broad incumbents

  • uniQure: Established gene therapy company with AAV platform and programs in cardiovascular disease (e.g., AMT-101 for refractory angina using SERCA2a). Direct overlap on SERCA2a gene therapy mechanism and cardiovascular focus, but broader portfolio across multiple disease areas.
  • BioMarin Pharmaceutical: Commercial-stage gene therapy company with multiple approved and clinical-stage AAV products for rare diseases (e.g., Roctavian for hemophilia A). Comparable gene therapy modality and rare disease commercial strategy, though broader portfolio and much larger scale.
  • AskBio (Bayer): Acquired by Bayer; develops AAV-based gene therapies across multiple disease areas including cardiac (congestive heart failure program based on Hajjar's earlier SERCA2a work licensed from Dr. Hajjar). Highly relevant incumbent that previously licensed the underlying SERCA2a technology.

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing cell and exosome-based therapies for Duchenne muscular dystrophy and related cardiomyopathies. Direct overlap on DMD-CM indication and complementary cell/gene therapy modality for cardiac disease.
  • Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiac and CNS indications, including AAV-based therapies for genetic cardiomyopathies and Friedreich's ataxia cardiomyopathy. Directly comparable platform (AAV gene therapy), indication overlap (cardiac), and stage (clinical).
  • Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV-based therapies for rare diseases, with a cardiac program (RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy). Comparable platform technology and rare cardiac indication focus.
  • Lexeo Therapeutics (duplicate entry superseded): Omitted in favor of stronger direct peers above.
  • Tenaya Therapeutics: Clinical-stage biotech developing gene therapies for genetic and acquired heart disease, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy. Directly comparable AAV-based cardiac gene therapy platform and similar disease-modifying positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sardocor compliance and trust

Trust signal

Compliance2 records

Sardocor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sardocor leadership team

Management profile

Number of profiles

Profiles3 records

Sardocor funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sardocor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sardocor

What does Sardocor do?

Sardocor develops gene therapies for cardiac, pulmonary, and vascular diseases using recombinant AAV1/SERCA2a vectors delivered via a proprietary intracoronary method. Its lead candidate SRD-001 has 1,000 doses manufactured and is being advanced through three FDA IND-approved clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with additional pipeline programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Is Sardocor a public or private company?

Sardocor is a private company. It is classified as corporate owned and is currently operating.

When was Sardocor founded?

Sardocor was founded in 2019. It employs 11 to 50 people.

Where is Sardocor based?

Sardocor is headquartered in Boston, United States, in the North America region.

How does Sardocor make money?

One revenue line is on record: gene Therapy Commercialization.

Who are Sardocor's main competitors?

Broad incumbents on record are uniQure, BioMarin Pharmaceutical and AskBio (Bayer). Direct peers are Capricor Therapeutics, Lexeo Therapeutics, Rocket Pharmaceuticals, Lexeo Therapeutics (duplicate entry superseded) and Tenaya Therapeutics.

Does Sardocor have an API?

No public API is recorded for Sardocor.

What industry is Sardocor in?

Sardocor's product category is Cardiac Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales